nature portfolio

nature portfolio	Corresponding author(s): Adam Miner
•	Last updated by author(s): Sep 5, 2022
	2051 aparted by dutilol(5). 30p 3, 2022
Editorial Policy Checklist	
This form is used to ensure compliance with Nature Portfolio editorial policies please see our <u>editorial policies</u> site. All relevant questions on the form must be	
Competing interests	
Policy information about <u>competing interests</u> In the interest of transparency and to help readers form their own judgements of competing financial and/or non-financial interest in relation to the work described	
Competing interests declaration We declare that none of the authors have competing financial or non We declare that one or more of the authors have a competing interest	
Authorship	
Policy information about <u>authorship</u>	
Prior to submission all listed authors must agree to all manuscript contents, the author list after submission must be approved by all authors.	ithor list and its order and the author contribution statements. Any changes to
We have read the Nature Portfolio Authorship Policy and confirm tha	t this manuscript complies.
Policy information about Authorship: inclusion & ethics in global research	
All authors are encouraged to provide an "Inclusion & Ethics" statement where re	levant.
We have provided an "Inclusion & Ethics" statement.	
Data availability	
Policy information about <u>availability of data</u>	
Data availability statement All manuscripts must include a <u>data availability statement</u> . This statement should a - Accession codes, unique identifiers, or web links for publicly available datased - A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement ad	rts
We have provided a full data availability statement in the manuscript	

Data availability

Data availability statement

- Accession codes, unique identifiers, or web links for publicly available data
- A description of any restrictions on data availability

- For clinical datasets or third party data, please ensure that the statement
- We have provided a full data availability statement in the manuscri

Mandated accession codes (where applicable)

Confirm that all relevant data are deposited into a public repository and that accession codes are provided.

☐ All relevant accession codes are provided ☐ Accession codes will be available before publication ☒ No data with mandated deposition

Code availability

Policy information about availability of computer code

Code availability statement

For all studies using custom code or mathematical algorithm that is deemed central to the conclusions, the manuscript must include a statement under the heading "Code availability" describing how readers can access the code, including any access restrictions. Code availability statements should be provided as a separate section after the data availability statement but before the References.

We have provided a full code availability statement in the manuscript

Data presentation		
For all data presented in a plot, char	t or other visual representation confirm that:	
n/a Confirmed		
The format shows data distribution clearly (e.g. dot plots, box-and-whisker plots)		
Box-plot elements are defined (e.g. center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers)		
Clearly defined error bars are present and what they represent (SD, SE, CI) is noted		
Image integrity		
Policy information about image inte	grity	
We have read Nature Portfolio	s's image integrity policy and all images comply.	
Unprocessed data must be provid inadvertent duplications have occ	ed upon request. Please double-check figure assembly to ensure that all panels are accurate (e.g. all labels are correct, no urred during preparation, etc.).	
Where blots and gels are presente blot, and that unprocessed scans	ed, please take particular care to ensure that lanes have not been spliced together, that loading controls are run on the same match the corresponding figures.	
Additional policy con	osidorations	
Additional policy cor		
Some types of research require additional policy disclosures. Please	Does not apply Involved in the study	
indicate whether each of these apply to your study. If you are not	 ✓ Macromolecular structural data ✓ Unique biological materials 	
certain, please read the	Research animals and/or animal-derived materials that require ethical approval	
appropriate section before	Human embryos, gametes and/or stem cells	
selecting a response.	Human research participants	
	Clinical data	
	Archaeological, geological, and palaeontological materials	
Clinical studies		
Policy information about <u>clinical stu</u>	<u>dies</u>	
Clinical trial registration		
•	istration number from <u>ClinicalTrials.gov</u> or an equivalent agency in the manuscript.	
Phase 2 and 3 randomized controlled trials		
We have provided the <u>CONSORT checklist</u> with your submission.		
Yes No Not a phase 2/3 randomized controlled trial		
Tumor marker prognostic studies		
We have followed the REMARK reporting guidelines.		
Yes No Not a tumor marker prognostic study		
I certify that all the above inform	nation is complete and correct.	
Typed signature Adam Miner	Date Sep 5, 2022	
/1		